Children and adolescents sleeping poorly enough to require prescription medication represents a quiet public health signal — one that intensified during the pandemic years. Tracking this trend rigorously matters because the drug classes involved carry meaningfully different risk profiles, and early prescribing patterns shape long-term pharmacological habits in developing brains.
Drawing on Japan's JMDC Claims Database — one of the largest administrative health databases in Asia — researchers tracked hypnotic prescriptions for over 2.4 million children aged 2–18 between 2014 and 2023. The proportion receiving hypnotics rose from 0.4% to 1.0% over that decade, with adolescents and females showing the steepest climbs. Benzodiazepines and Z-drugs declined in use, while melatonin receptor agonists and dual orexin receptor antagonists rose sharply. Interrupted time-series analysis detected a statistically significant acceleration in the prescribing slope after Japan's April 2020 state of emergency — roughly 3.64 additional prescriptions per 100,000 children per month — though no abrupt jump at that threshold.
Several dimensions of this finding deserve careful weighing. The shift away from benzodiazepines toward melatonin receptor agonists reflects a deliberate clinical evolution toward compounds with more favorable pediatric safety profiles, which is broadly positive. However, the pandemic-linked acceleration persisting primarily among adolescents — even when melatonin is excluded from analysis — suggests structural disruptions to sleep architecture, not merely prescribing convenience. Disrupted circadian rhythms from school closures, increased screen exposure, and social isolation likely drove genuine clinical need. That said, this is an observational claims-database study, meaning diagnostic context, severity, and physician rationale are absent. Whether rising prescription rates reflect better recognition of a pre-existing problem or a genuine worsening of pediatric insomnia post-pandemic remains unresolved. For health-conscious parents and clinicians, the data reinforce that adolescent sleep dysfunction warrants early behavioral intervention before pharmacological escalation becomes routine.